In this review:
This review is intended as an educational resource for healthcare professionals.
The review presents relevant background information on chronic spontaneous urticaria (CSU) and focuses on pharmacologic management strategies. In particular, it highlights the use of omalizumab in patients with CSU who remain symptomatic despite H1 antihistamine treatment.
Download PDF